Home › Employers › SPI Pharma, Inc.
SPI Pharma, Inc.: H-1B salaries and sponsorship
SPI Pharma, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $100,000.
Does SPI Pharma, Inc. sponsor H-1B visas?
SPI Pharma, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 7, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Product Manager, Excipients and Drug Delivery Systems | 2 | $100,232 |
| Quality Control Team Leader | 1 | $81,536 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 1 | $100,000 |
| FY2025 | 1 | $81,536 |
| FY2026 | 1 | $100,464 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Product Manager, Excipients and Drug Delivery Systems | $100,464–$130,000 Level II | Wilmington, DE | Apr 7, 2026 | Sep 30, 2026 | Certified |
| Quality Control Team Leader | $81,536–$86,536 Level II | Lewes, DE | Jun 9, 2025 | Oct 1, 2025 | Certified |
| Product Manager, Excipients and Drug Delivery Systems | $100,000–$120,000 Level II | Wilmington, DE | May 15, 2023 | Sep 30, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).